All stocks Β· MERCURYLAB
ML

Mercury Laboratories Limited

MERCURYLAB BSE Drug Manufacturers - Specialty & Generic Healthcare

Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analg…

ISIN INE947G01011
Listed β€”
Quarters tracked 13
Filings 19 docs

About

Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-allergic, steroids, urinary system, uterine stimulant, and other drugs; and formulations, including tablets, oral liquids, injections, small volume parenterals, and eye/ear drops. It also provides pharmaceutical products for PCOS and uterine disorders, galactagogue, haemostat, iron and vitamins, pain management, preterm labor management, antiemetic, PPI; vitamin K1, zinc supplement, antiallergic, vitamin D3, digestive enzyme, promolact, antipyretic, and childcare, as well as products for gynec, pediatric, surgeon, and physician applications. The company export its products comprising anti-inflammatory, antimalarial, digestive, hypoglycemic, multivitamin, CNS, pain management, gynec, CVS, cough and cold, miscellaneous, and other formulations, as well as antibiotic, antifungal, and antiviral formulations to approximately 25 countries, including the Philippines, Myanmar, Sri Lanka, Vietnam, Cambodia, D.R. Congo, Ghana, Nigeria, Mozambique, Zambia, Kenya, lvory Coast, Mauritania, Burundi, Togo, Guatemala, Costa Rica, Peru, Ecuador, the United Kingdom, the United States, Moldova, and Jamaica. Mercury Laboratories Limited was founded in 1962 and is headquartered in Vadodara, India.

Quarterly Results

Rs. Crores Β· hover row for definition
Metric Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023
Sales 15.96 20.44 18.35 19.01 18.14 20.66 19.57 18.19 16.68 17.37 17.11 22.76 18.32
Expenses 14.77 18.40 15.83 16.88 15.78 18.53 17.59 16.88 15.07 14.71 14.88 20.28 16.66
Operating Profit 1.19 2.04 2.52 2.13 2.36 2.13 1.98 1.31 1.61 2.66 2.23 2.48 1.66
OPM % 7.46 9.98 13.73 11.20 13.01 10.31 10.12 7.20 9.65 15.31 13.03 10.90 9.06
Other Income 0.05 0.67 -0.08 0.79 0.18 0.18 0.53 0.21 0.15 0.41 0.18 0.36 0.15
Depreciation 0.73 0.84 0.87 0.86 0.84 0.73 0.74 0.71 0.70 0.72 0.72 0.71 0.68
Interest 0.12 0.13 0.14 0.13 0.15 0.13 0.13 0.15 0.14 0.10 0.10 0.11 0.08
Profit before tax 0.39 1.74 1.43 1.93 1.55 1.45 1.64 0.66 0.92 2.25 1.59 2.02 1.05
Tax % 23.08 29.31 30.77 14.51 37.42 23.45 27.44 22.73 63.04 15.11 22.01 25.74 5.71
Net Profit 0.30 1.23 1.00 1.64 0.97 1.11 1.19 0.50 0.34 1.91 1.24 1.51 1.00
EPS in Rs 2.50 10.25 8.33 13.67 8.08 9.25 9.92 4.17 2.83 15.92 10.33 12.58 8.33

Profit & Loss

Annual Β· Rs. Crores
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
Sales 75.9475.1075.5675.3357.9268.6057.2755.5251.8648.0247.5141.19
Expenses 66.9168.0866.5366.7350.9259.0151.1049.7947.4441.3041.0435.40
Operating Profit 9.037.029.038.607.009.596.175.734.426.726.475.79
OPM % 11.899.3511.9511.4212.0913.9810.7710.328.5213.9913.6214.06
Other Income 1.571.071.091.690.940.880.851.040.420.350.781.12
Interest 0.540.550.380.360.450.640.821.090.910.891.131.12
Depreciation 3.422.882.822.482.451.921.871.631.471.291.181.18
Profit before tax 6.644.666.927.455.047.914.334.052.464.894.944.61
Tax % 27.1132.6218.3524.9729.1732.4925.4029.8817.8944.7920.4527.98
Net Profit 4.833.145.655.583.565.343.232.842.012.703.923.31
EPS in Rs 40.2526.1747.0846.5029.6744.5026.9223.6716.7522.5032.6727.58
Dividend Payout % 8.7013.387.437.5311.807.877.436.348.966.674.595.44

Balance Sheet

Annual Β· Rs. Crores β€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
Equity Capital 1.201.201.201.201.201.201.201.201.201.201.201.20
Reserves 56.8852.3749.6444.4339.1135.6930.7827.7725.1523.2720.6516.94
Borrowings 8.425.455.555.835.997.107.199.569.767.447.378.88
Other Liabilities 12.5815.2111.5612.7016.1421.3817.1318.7615.5919.2317.3015.50
Total Liabilities 79.0874.2367.9564.1662.4465.3756.3057.2951.7051.1446.5242.52
Fixed Assets 23.8924.6424.0324.2625.8226.3623.6624.3920.7818.3918.5719.48
CWIP 9.829.323.820.130.000.000.000.000.240.400.000.00
Investments 0.010.010.010.010.010.010.010.010.010.010.010.01
Other Assets 45.3640.2640.0939.7636.6139.0032.6332.8930.6732.3427.9423.03
Total Assets 79.0874.2367.9564.1662.4465.3756.3057.2951.7051.1446.5242.52

Cash Flows

Annual Β· Rs. Crores β€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
Cash from Operating Activity 4.244.008.232.455.198.215.495.224.971.92-0.103.49
Cash from Investing Activity -3.17-9.04-6.27-1.06-1.89-4.62-1.14-4.99-3.68-1.50-0.28-1.54
Cash from Financing Activity 2.63-0.99-1.04-1.01-1.23-1.24-3.33-2.541.07-0.250.47-2.12
Net Cash Flow 3.71-6.030.910.382.072.361.02-2.312.360.170.09-0.18
Free Cash Flow 1.07-5.041.961.393.303.594.350.231.290.42-0.381.95
CFO/OP % 61.0091.00105.0041.00101.00100.00109.00109.00129.0045.0020.0082.00

Ratios

Annual Β· Days / % β€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
Debtor Days 124.25125.10105.55103.55105.49119.93115.61126.82103.60133.25103.02107.84
Inventory Days 88.0192.4775.8882.82104.5960.4278.4493.95119.80137.30115.5093.92
Days Payable 77.13126.0763.3076.58105.98137.94120.01161.71138.65186.56136.34159.39
Cash Conversion Cycle 135.1291.50118.13109.79104.1042.4174.0459.0584.7583.9982.1942.37
Working Capital Days 130.16110.8691.6487.0279.0275.0288.7888.7590.58102.8446.869.22
ROCE % 12.068.9413.4116.0411.8320.5613.2613.779.8218.9121.5921.35

Shareholding Pattern

% holding β€” latest first
Holder Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023
Promoters 73.66 73.66 73.66 73.66 73.66 73.66 73.66 73.66 73.66 73.66 73.66 73.66
Public 26.34 26.34 26.35 26.34 26.34 26.34 26.34 26.36 26.35 26.34 26.35 26.34
No. of Shareholders 1,328 1,316 1,321 1,365 1,384 1,397 1,411 1,345 1,259 1,214 1,161 1,149

Corporate Actions

11 records
ActionEx DateRecord DateRatioAmount (β‚Ή)Notes
Dividend 06 Aug 2025 06 Aug 2025 β€” 3.50
Dividend 20 Sep 2024 β€” β€” 3.50
Dividend 20 Sep 2023 β€” β€” 3.50
Dividend 19 Sep 2022 β€” β€” 3.50
Dividend 20 Sep 2021 β€” β€” 2.00
Dividend 22 Feb 2021 23 Feb 2021 β€” 1.50
Dividend 21 Sep 2020 β€” β€” 2.00
Dividend 19 Sep 2019 β€” β€” 1.50
Dividend 31 Aug 2018 β€” β€” 1.50
Dividend 15 Sep 2017 β€” β€” 1.50
Dividend 16 Sep 2015 β€” β€” 1.50

Announcements

5 filings